Grades and Levels of Evidence: Difference between revisions
Tyler Shultz (talk | contribs) No edit summary |
Tyler Shultz (talk | contribs) No edit summary |
||
| Line 34: | Line 34: | ||
| Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses<br> | | Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses<br> | ||
|- | |- | ||
| 1C<br> | | '''1C'''<br> | ||
| <br> | | All or none series<br> | ||
| <br> | | All or none case serires<br> | ||
| <br> | | Absoulute [[Test_Diagnostics|SpPins and SnNouts]]<br> | ||
| <br> | | All or none case series<br> | ||
| <br> | | Absolute better-value or worse-value analyses<br> | ||
|- | |- | ||
| 2A<br> | | '''2A'''<br> | ||
| <br> | | SR (with homogeneity) of cohort studies<br><br> | ||
| <br> | | SR (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs<br> | ||
| <br> | | SR (with homogeneity) of Level >2 diagnostic studies<br> | ||
| <br> | | SR (with homogeneity) of 2b and better studies<br> | ||
| <br> | | SR (with homogeneity) of Level >2 economic studies<br> | ||
|- | |- | ||
| 2B<br> | | 2B<br> | ||
Revision as of 16:31, 8 June 2009
Original Editor - Tyler Shultz
Lead Editors - Your name will be added here if you are a lead editor on this page. Read more.
Discussion & Background[edit | edit source]
Levels of Evidence[edit | edit source]
| Level |
Therapy/Prevetion, Aetiology/Harm |
Prognosis |
Diagnosis |
Differential Diagnosis |
Economic and Descision Analysis |
| 1A |
SR (with homogeneity) of RCTs |
SR (with homogeneity) of inception cohort studies; CDR validated in different populations |
SR (with homogeneity) of Level 1 diagnostic studies; CDR with 1b studies from different clinical centres |
SR (with homogeneity) of prospective cohort studies |
SR (with homogeneity) of Level 1 economic studies |
| 1B |
Individual RCT (with narrow Confidence Interval) |
Individual inception cohort study with > 80% follow-up; CDR validated in a single population |
Validating cohort study with good reference standards; or CDR tested within one clinical centre |
Prospective cohort study with good follow-up |
Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses |
| 1C |
All or none series |
All or none case serires |
Absoulute SpPins and SnNouts |
All or none case series |
Absolute better-value or worse-value analyses |
| 2A |
SR (with homogeneity) of cohort studies |
SR (with homogeneity) of either retrospective cohort studies or untreated control groups in RCTs |
SR (with homogeneity) of Level >2 diagnostic studies |
SR (with homogeneity) of 2b and better studies |
SR (with homogeneity) of Level >2 economic studies |
| 2B |
|||||
| 2C |
|||||
| 3A |
|||||
| 3B |
|||||
| 4 |
|||||
| 5 |
Grades of Evidence[edit | edit source]
Recent Related Research (from Pubmed)[edit | edit source]
Extension:RSS -- Error: Not a valid URL: Feed goes here!!|charset=UTF-8|short|max=10
References[edit | edit source]
